Clinical Pharmacology of Current Antiepileptic Drugs
DOI:
https://doi.org/10.37285/ijpsn.2014.7.1.1Abstract
This article describes current antiepileptic drugs (AEDs) that are available for treatment of epilepsy. Epilepsy is characterized by repeated occurrence of seizures, which are clinical manifestations of abnormal electrical discharges in the brain. Epileptic seizures arise from a multiplicity of factors that regulate neuronal excitability and synchrony. Epilepsy is caused because of certain genetic defects or acquired due to brain injury. Epileptic seizures are classified into partial (simple partial and complex partial) and generalized (absence, tonic-clonic, myoclonic, and atonic seizures) types. Around two-dozen AEDs, classified as standard and newer agents, are available for treating epilepsy. AEDs act on diverse molecular targets to selectively modify the abnormal excitability of neurons by reducing the focal seizure discharges or preventing spread of excitation. AEDs suppress seizures by blocking the voltage-gated sodium channels (phenytoin, carbamazepine, valproate, lamotrigine, oxcarbazepine, topiramate), voltage-activated calcium channels (ethosuximide, gabapentin), potentiation of GABA inhibition (barbiturates, benzodiazepines, tiagabine), and reduction of glutamate excitation (felbamate). Carbamazepine, phenytoin, and valproate are the first-line agents for partial seizures and generalized tonic-clonic seizures. Ethosuximide is the drug of choice for absence seizures. Intravenous benzodiazepines diazepam or lorazepam are effective in terminating status epilepticus. AEDs are orally-active and show unique pharmacokinetic features. Some AEDs cause enzyme induction and hence produce drug interactions. Newer AEDs such as gabapentin, levetiracetam, tiagabine, zonisamide and pregabalin do not cause enzyme induction. Treatment in pregnancy must consider optimizing therapy while preventing teratotoxicity of AEDs. There are alternative options (ketogenic diet) for children. Despite many advances in epilepsy research, nearly 30% of people with epilepsy have “intractable seizures” that do not respond to drug therapy. Presently, there is no cure for epilepsy. Therefore, newer and better AEDs that can better prevent seizures and modify the disease are needed for curing epilepsy.
Downloads
Metrics
Keywords:
Epilepsy, seizure, epileptogenesis, phenytoin, carbamazepine, valproate, ethosuximide, tiagabine
Downloads
Published
How to Cite
Issue
Section
References
Berg ET, Berkovic SF and Brodie MJ (2010). Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51: 676-685.
Brodie MJ and Kwan P (2002). Staged approach to epilepsy management. Neurology 58(suppl 5): S2-S8.
Brodie MJ, Richens A and Yuen AW (1995). Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 345: 476-479.
Brophy, GM, Bel,l R, Claassen J, Alldredge B, Bleck TP, Glauser T.;, Laroche SM, Riviello JJ Jr, Shutter L, Sperling MR, Treiman DM and Vespa PM (2012). Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17, 3-23.
Cendes, F (2005). Progressive hippocampal and extra hippocampal atrophy in drug resistant epilepsy. Current Opinion in Neurology 18: 173-177.
Chadwick DW, Anhut H and Greiner MJ (1998). A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 51:1282-1288.
Delgado-Escueta AV, Wasterlain C, Treiman DM and Porter R.J. (1983). Status epilepticus: summary. Adv. Neurol. 34: 537-541.
DeLorenzo RJ, Towne AR, Pellock JM and Ko D (1992). Status epilepticus in children, adults, and the elderly. Epilepsia 33 (Suppl 4): S15-25.
Diaz RA, Sancho J and Serratosa J (2008). Antiepileptic drug interactions. Neurologist 14(suppl 1): S55-S65.
Dudek FE and Staley KJ (2011). The time course of acquired epilepsy: implications for therapeutic intervention to suppress epileptogenesis. Neurosci Lett 497: 240-246.
Duncan JS, Sander JW, Sisodiya SM and Walker MC (2006). Adult epilepsy. Lancet 367(9516): 1087-1100.
Engel J Jr (1993). Clinical neurophysiology, neuroimaging, and the surgical treatment of epilepsy. Curr. Opin. Neurol. Neurosurg 6(2): 240-249.
French JA, Kanner AM, Bautista MD, et al., (2004). Efficacy and tolerability of the new antiepileptic drugs. I: Treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62:1252-1260.
French JA and Pedley TA (2008). Clinical practice. Initial management of epilepsy. N Engl J Med. 359(2): 166-76.
Gluaser T, Ben-Menachem E, Bourgeois B, et al., (2006). ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47: 1094-1120.
Harden CL et al. (2009). Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): part I, II, and III. Epilepsia 50(5): 1229-36 (part I), 1237-46 (part II),1247-55 (part III).
Hesdorffer DC, Beck V et al., (2013). Research implications of the Institute of Medicine Report, Epilepsy Across the Spectrum: Promoting Health and Understanding. Epilepsia 54: 207-216.
ILAE (1981). Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22: 489-501.
Jacobs MP, Leblanc, GG et al., (2009). Curing epilepsy: progress and future directions. Epilepsy Behav 14: 438-445.
Köhling R and Staley K (2011). Network mechanisms for fast ripple activity in epileptic tissue. Epilepsy Res 97: 318-323.
Lowenstein DH (2012). Seizures and epilepsy. In: Fauci AS, Kasper DL, Jameson JL, et al, eds. Harrison’s Principles of Internal Medicine. 18th ed. New York: The McGraw Hill Companies.
Mani R, Pollard J and Dichter MA (2011). Human clinical trails in antiepileptogenesis. Neurosci Lett 497: 251-256.
Marson AG, Al-Kharusi AM, Alwaidh M, et al., (2007a). The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet 369: 1000-1015.
Marson AG, Al-Kharusi AM, Alwaidh M, et al (2007b). The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial. Lancet 369: 1016-1026.
Mattson RH, Cramer JA, Collins JF, et al (1985). Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 313: 145-151.
Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ and Fitzsimmons BF (2002). Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 59(2): 205-210.
McNamara JO (2006). Pharmacotherapy of the epilepsies. In gmgm pharmacological basis of therapeutics, 11th edition. Brunton LL, Lazo, JS, Parker KL, eds. McGraw Hill: 501-525.
Meador KJ (2006). Cognitive and memory effects of new antiepileptic drugs. Epilepsy Res 68: 63-67.
Patsalos PN, Berry DJ, Bourgeois BF, et al (2008). Antiepileptic drugs—best practice guideline for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49: 1239-1276.
Pennel PB (2008). Antiepileptic drugs during pregnancy: What is known and which AEDs seem to be safest? Epilepsia 49 (Suppl.9): 43-55.
Pitkänen A. and Lukasiuk K. ( 2011). Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 10: 173-186.
Rao M.S., Hattiangady B., Reddy D.S. and Shetty A.K. (2006). Hippocampal neurodegeneration, spontaneous seizures, and mossy fiber sprouting in the F344 rat model of temporal lobe epilepsy. J Neurosci Res. 83: 1088-1105.
Reddy DS (2010). Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Exp Rev Clin Pharmacol. 3(3): 1-10.
Reddy DS (2013). Role of hormones and neurosteroids in epileptogenesis. Frontiers in Cellular Neuroscience 7(article 115): 1-20.
Reddy D.S. (2009). The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res 85: 1-30.
Reddy D.S. (2011). Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy. Front Endocrinol 2 (article 38): 1-18.
Reddy DS and Mohan A (2011). Development and persistence of limbic epileptogenesis are impaired in mice lacking progesterone receptors. J Neurosci. 31: 650-658.
Reddy DS and Kuruba R (2013). Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. Int J Mol Sci 14: 18284-18318.
Rogawski MA and Löscher W (2004). The neurobiology of antiepileptic drugs. Nature Rev Neuroscience 5: 553-64.
Rogers SJ and Cavazos JE (2005). In: Talbert RL, DiPiro JT, Matzke GR, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York, NY: The McGraw Hill Companies; Epilepsy.
Schachter SC (2007). Curently available antiepileptic drugs. Neurotherapeutics 4: 4-11.
Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W, et al., (2012). Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 366: 591-600.
Stafstrom CE, Zupec-Kania B and Rho JM (2008). Ketogenic diet and related dietary treatments. Epilepsia 49 (Suppl. 8.): 1-2.
Stecker MM, Kramer TH, Raps EC, O'Meeghan R, Dulaney E and Skaar DJ (1998). Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia. 39: 18-26.
Stringer JL (1998). Drugs for Seizure Disorders. In Human Pharmacology: Molecular to Clinical, 3rd edition. TM Brody, J Larner, KP Minneman, eds. Mosby-Year Book, Epilepsies: 373-383.
Sutula TP (2004). Mechanisms of epilepsy progression: current theories and perspectives from neuroplasticity in adulthood and development. Epilepsy Re 60: 161-171.
Temkin NR (2001). Antiepileptogenesis and seizure prevention trials with antiepileptic drugs, meta-analysis of controlled trials. Epilepsia 42: 515-524.
Tomson T, Perucca E and Battino D (2004). Navigating toward fetal and maternal health: The challenge of treating epilepsy in pregnancy. Epilepsia 45: 1171-1175.
Vivas AC, Baaj AA, Benbadis SR and Vale FL (2012). The health care burden of patients with epilepsy in the United States: An analysis of a nationwide database over 15 years. Neurosurg Focus 32: E1.
Wheless JW and Treiman DM (2008). The role of the newer antiepileptic drugs in the treatment of generalized convulsive status epilepticus. Epilepsia 49(Suppl 9), 74-78.
White HS and Rho JM (2010). Mechanisms of action of antiepileptic drugs. Professional Communications, Inc.
